F*CK CANCER
9 min readFrom Chapter 14 — Personalized Cancer Treatment: Tailoring the Fight of the book

Personalized Cancer Treatment: How Genomics Tailors Your Fight

Next-generation sequencing, liquid biopsies, NTRK inhibitors — how precision oncology matches the treatment to your tumor’s exact mutations. Chapter 14 of F*CK CANCER.

personalized cancer treatmentprecision oncologynext-generation sequencingNTRK inhibitorsliquid biopsy

For most of medical history, cancer treatment was organized by geography: lung cancer got lung-cancer drugs, breast cancer got breast-cancer drugs. Chapter 14 of the book is about the revolution that replaced that logic — treating the tumor not by where it grows, but by what it is, down to its exact genetic mutations. This is personalized oncology, and for many patients it has already changed everything.

Read the tumor's playbook

Next-Generation Sequencing (NGS) reads the DNA of a patient's tumor and lists its mutations — the specific broken genes driving that specific cancer. Two patients with the "same" cancer can have tumors with entirely different mutational fingerprints, and that fingerprint increasingly decides the treatment. The chapter teaches patients to ask the question that matters: has my tumor been sequenced? — because a surprising number never are, even when the results could open doors to targeted drugs or trials.

Drugs that aim at mutations, not organs

The proof of the new logic is the NTRK Inhibitors: drugs approved not for a cancer type but for a cancer mutation. If a tumor — any tumor, in any organ, in a child or an adult — carries an NTRK gene fusion, these drugs target it, with response rates that made even seasoned oncologists stare. The chapter pairs these with the broader class of Targeted Kinase Inhibitors — drugs like Gleevec, the molecule that turned a fatal leukemia into a manageable condition by aiming at its exact driving mutation — and explains how to find out whether your tumor carries a targetable alteration.

Liquid biopsies: the monitor in the bloodstream

Chapter 14 connects sequencing to its partner technology: the Liquid Biopsy, which detects tumor DNA shed into the blood. Together they form a complete precision loop — sequence the tumor to find its weakness, treat the weakness, then monitor the blood for the earliest sign that the tumor is changing tactics. A liquid biopsy can spot resistance mutations emerging months before a scan shows growth, buying the one thing cancer patients can never have enough of: time to adjust.

The era of one-size-fits-all oncology is ending. The era of your tumor, your mutations, your treatment has begun.

The questions this chapter arms you with

Has my tumor been genetically profiled? Does it carry mutations with approved targeted drugs? Are there trials matched to my tumor's profile? Should a liquid biopsy be part of my monitoring? These are the questions Chapter 14 teaches you to bring to your oncology team — and the technologies behind them are profiled in the free Cure Finder. The full chapter, including how personalized medicine connects to the metabolic and immune strategies of the earlier chapters, is in the book.

Educational content, not medical advice. Genomic testing and treatment selection belong with your oncology team.

Frequently asked questions

What is genomic testing for cancer?

Genomic testing sequences a tumor’s DNA to find the mutations driving it. Results can match patients to targeted drugs, immunotherapies, or clinical trials that would never be considered based on the cancer’s location alone.

What are NTRK fusion drugs?

Larotrectinib and entrectinib treat any cancer carrying an NTRK gene fusion, regardless of where in the body it started. They produce remarkable responses in these rare tumors — the purest example of precision oncology.

How do I get a tumor sequenced?

Ask the oncology team directly for comprehensive genomic profiling or next-generation sequencing of tumor tissue or a liquid biopsy. Major cancer centers offer it routinely, and many insurers now cover it for advanced disease.